Top News in R&D
 
 

 

 

READ ONLINE

 

 
 
 
 Global Health Technologies Coalition 
 
 
 
 

 

R&D News Roundup: October 10, 2022

 

Top News in R&D

A bold effort to cure HIV—using Crispr
WIRED (10/5)

Excision BioTherapeutics is investigating whether a single Crispr infusion can effectively keep HIV at undetectable levels in the body. If effective, this innovation could eliminate the need for daily antiretroviral therapy. The Crispr therapy attempts to disrupt the replication process by targeting regions in the HIV genome that are critical in that process. While antiretroviral drugs can stop the virus from replicating, the Crispr therapy is designed to go further by ensuring that the virus cannot reactivate in the future. The trial aims to enroll nine participants and compare the efficacy of three different dosages.

Shionogi and the Medicines Patent Pool reach agreement on COVID-19 antiviral pill
Health Policy Watch (10/4)
Additional coverage from Devex (10/4)

The Medicines Patent Pool has signed a voluntary licensing agreement with Japanese pharmaceutical company Shionogi, to allow low- and middle-income countries (LMICs) rapid access to its COVID-19 antiviral treatment pill, contingent on its regulatory approval. Under the agreement, the Medicines Patent Pool will grant sub-licenses to qualified generic manufacturers to produce the antiviral (ensitrelvir fumaric acid) in 117 LMICs. The candidate, which showed promising results in phase 2/3 trials, could make a significant difference in low-and middle-income countries with low vaccination rates.

Vir Biotech gets US funding for flu-prevention antibody
Reuters (10/4), features Vir Biotechnology

The Biomedical Advanced Research and Development Authority has granted a multi-year contract to Vir Biotechnology with US$55 million in funding to support its influenza-focused antibody drug that is expected to continue trials soon. The contract also allows for a potential billion-dollar investment for the development of candidates against emerging infectious diseases, including influenza. The funding is aimed at improving pandemic preparedness efforts through investments in technologies that target pathogens with pandemic potential.

 

 

News from GHTC

Sharp disagreement over intellectual property at WHO pandemic treaty donsultation
Health Policy Watch (10/8), features the Coalition for Epidemic Preparedness Innovations (CEPI)

EU-funded project to develop infectious disease tests, digital health infrastructure for Africa
360Dx (10/7), features the Bill & Melinda Gates Foundation

CEPI partners with Intravacc to develop an intranasal, broadly protective Betacoronavirus vaccine
CEPI press release (10/6)

The malaria vaccine could be a game-changer for global development
Axios (10/6), features PATH

CARB-X notes new funding rounds to address superbugs
CIDRAP (10/5), features Boston University Institute for Health System Innovation & Policy’s Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)

Weak systems and lack of investment in new antibiotics are key global health threats
Health Policy Watch (10/5), features Drugs for Neglected Diseases initiative

Will we ever have a vaccine for HIV?
AARP sponsored article (10/4), features IAVI

At long last, can malaria be eradicated?
The New York Times (10/4), features the Gates Foundation

Twenty minutes HIV self-test kit likely to be in India by December
The Times of India (10/3), features PATH

Achieving health for all through research and development
TB Alliance LinkedIn article (10/3)

 

 

Highlights From the Week

 

 

COVID-19 R&D spotlight

 

 

Monkeypox R&D spotlight

 

 

Upcoming Events

October 12
Global Health Impact Awards
Seattle, Washington

October 13
Virtual policy briefing: Update from DC
Virtual

October 19-23
IDWeek
Washington, DC; Virtual

October 21
OSTP dialogue on first report on AP3 annual report
Virtual

October 30-November 3
ASTMH 2022 Annual Meeting
Seattle, Washington

November 14
2022 Research in Action Awards
New York, New York

December 7-8
2022 Global Health Landscape Symposium
Virtual